SEC Form 4
Xenon Pharmaceuticals Inc (XENE) insider trading
In the 12 months to Oct 26, 2026, 5 XENE insiders reported open-market sales of $20.4M across 8 filings; 2 insiders bought $1.7M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $20.4M
- 8 filings · 5 insiders
- Open-market purchases
- $1.7M
- 2 filings
- Pre-arranged sales (10b5-1)
- 7 of 8
- $19.8M of $20.4M sold (97%)
Who traded XENE, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
XENE daily close from Oct 27, 2025 to Oct 26, 2026, between $33.49 and $70.96, last $35.57. 8 sale and 2 purchase filings by 6 insiders, marked at their filing dates. Ian Mortimer, PRESIDENT & CEO: sold $19.2M and bought $1.1M across 5 filings, first filed Dec 3, 2025, last Oct 1, 2026. Steven Gannon, Director: sold $640.6K across 1 filing, first filed Aug 13, 2026, last Aug 13, 2026. Thomas Patrick Kelly, Chief Financial Officer: bought $559.7K across 1 filing, first filed Oct 1, 2026, last Oct 1, 2026. Christopher John Kenney, Chief Medical Officer: sold $425.8K across 1 filing, first filed Aug 31, 2026, last Aug 31, 2026. Gary Patou, Director: sold $70.3K across 1 filing, first filed Jun 8, 2026, last Jun 8, 2026. Gillian Cannon, Director: sold $63.2K across 1 filing, first filed Jun 8, 2026, last Jun 8, 2026.
Largest mark · tap a row for others
Ian Mortimer · PRESIDENT & CEO
Sale $16,289,143
270,000 shares at $60.33 avg
Filed Mar 11, 2026 · traded Mar 9
Pre-arranged (10b5-1) · close on filing date $59.04
Ian Mortimer · PRESIDENT & CEO
PRESIDENT & CEO
$19.2M sold$1.1M boughtSteven Gannon · Director
Director
$640.6K soldThomas Patrick Kelly · Chief Financial Officer
Chief Financial Officer
$559.7K boughtChristopher John Kenney · Chief Medical Officer
Chief Medical Officer
$425.8K soldGary Patou · Director
Director
$70.3K soldGillian Cannon · Director
Director
$63.2K soldOpen-market trades
10 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO | $19.2M | $1.1M | 5 | 100% of sales | |
| Steven Gannon | Director | $640.6K | — | 1 | — | |
| Thomas Patrick Kelly | Chief Financial Officer | — | $559.7K | 1 | — | |
| Christopher John Kenney | Chief Medical Officer | $425.8K | — | 1 | 100% of sales | |
| Gary Patou | Director | $70.3K | — | 1 | 100% of sales | |
| Gillian Cannon | Director | $63.2K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Ian Mortimer PRESIDENT & CEO | Purchase | 30,000 | $37.38 | $1.1M | 49,923 | |
traded | Thomas Patrick Kelly Chief Financial Officer | Purchase | 15,000 | $37.32 | $559.7K | 15,000 | |
traded | Christopher John Kenney Chief Medical Officer | SalePre-arranged (10b5-1) | 7,068 | $60.25 | $425.8K | 2 | |
traded | Steven Gannon Director | Sale | 10,000 | $64.06 | $640.6K | 1,870 | |
traded | Gillian Cannon Director | SalePre-arranged (10b5-1) | 1,190 | $53.14 | $63.2K | 1,455 | |
traded | Gary Patou Director | SalePre-arranged (10b5-1) | 1,322 | $53.14 | $70.3K | 24,896 | |
traded | Ian Mortimer PRESIDENT & CEO | SalePre-arranged (10b5-1) | 270,000 | $60.33 | $16.3M | 27,515 | |
traded | Ian Mortimer PRESIDENT & CEO | SalePre-arranged (10b5-1) | 40,000 | $44.43 | $1.8M | 6,000 | |
traded | Ian Mortimer PRESIDENT & CEO | SalePre-arranged (10b5-1) | 25,205 | $45.33 | $1.1M | 6,000 | |
traded | Ian Mortimer PRESIDENT & CEO | SalePre-arranged (10b5-1) | 97 | $45.01 | $4.4K | 31,205 |
GET /stocks/filings/vX/form-4?tickers=XENE&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"XENE"
],
"issuer_cik": "0001582313",
"owner_cik": "0001410514",
"accession_number": "0001193125-26-410001",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-30",
"issuer_name": "Xenon Pharmaceuticals Inc.",
"issuer_trading_symbol": "XENE",
"owner_name": "Kelly Thomas Patrick",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-30",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 15000,
"transaction_price_per_share": 37.316,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 15000,
"transaction_value": 559740,
"direct_or_indirect": "D"
},
{
"tickers": [
"XENE"
],
"issuer_cik": "0001582313",
"owner_cik": "0001619961",
"accession_number": "0001193125-26-409999",
"form_type": "4",
"filing_date": "2026-10-01",
"period_of_report": "2026-09-30",
"issuer_name": "Xenon Pharmaceuticals Inc.",
"issuer_trading_symbol": "XENE",
"owner_name": "MORTIMER IAN",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "PRESIDENT & CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-30",
"transaction_code": "P",
"equity_swap_involved": false,
"transaction_shares": 30000,
"transaction_price_per_share": 37.38,
"transaction_acquired_disposed": "A",
"shares_owned_following_transaction": 49923,
"transaction_value": 1121400,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 29 records
- Option exercises21 records
- Tax withholding2 records
- Tax withholding (sold to cover)6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Xenon Pharmaceuticals Inc's CEO sold stock?
Yes. Ian Mortimer (CEO) sold 335,302 shares ($19.2M) between Dec 2025 and Mar 2026, all under a pre-arranged 10b5-1 plan.
How current is XENE’s insider data?
These are XENE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track XENE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for XENE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.